Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.

Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers.
复制标题

基质因子是黑色素瘤和非黑色素瘤皮肤癌的免疫疗法的靶标。

DOI:
10.3390/ijms23074044
复制
发表时间:
2022-04-06
影响因子:
5.6
通讯作者:
Fujimura T
Fujimura T
中科院分区:
生物学2区
文献类型:
--
作者:
Fujimura T

文献摘要

参考文献

被引文献

相似文献

免疫检查点抑制剂(ICI),如抗程序性细胞死亡1(PD 1)抗体(Ab)和抗细胞毒性T淋巴细胞相关蛋白4(CTLA 4)Ab,不仅已被广泛用于晚期黑色素瘤,而且还用于各种非黑色素瘤皮肤癌。由于肿瘤浸润性白细胞(TIL)的特征在使用ICI的免疫治疗中起重要作用,因此评估癌症基质细胞(如肿瘤相关巨噬细胞(TAM)和癌症相关成纤维细胞(CAF))以及基质细胞外基质蛋白以预测ICI的疗效是重要的。这篇综述文章特别关注TAM及其相关因素。在TIL中,TAM及其相关因子可能是免疫治疗如抗PD1 Ab治疗的最佳生物标志物。根据这些研究,未来将开发针对晚期黑色素瘤和非黑色素瘤皮肤癌的TAM靶向治疗。
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1) antibodies (Abs) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) Abs, have been widely administered for not only advanced melanoma, but also various non-melanoma skin cancers. Since profiles of tumor-infiltrating leukocytes (TILs) play important roles in immunotherapy using ICIs, it is important to evaluate cancer stromal cells such as tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), as well as stromal extracellular matrix protein, to predict the efficacy of ICIs. This review article focuses particularly on TAMs and related factors. Among TILs, TAMs and their related factors could be the optimal biomarkers for immunotherapy such as anti-PD1 Ab therapy. According to the studies presented, TAM-targeting therapies for advanced melanoma and non-melanoma skin cancer will develop in the future.
默克尔细胞癌衍生的外泌体 - 丝业miR-375通过抑制RBPJ和p53诱导成纤维细胞极化。
DOI: 10.1038/s41388-020-01576-6
发表时间: 2021-03
期刊: Oncogene
影响因子: 8
作者:
Fan K;Spassova I;Gravemeyer J;Ritter C;Horny K;Lange A;Gambichler T;Ødum N;Schrama D;Schadendorf D;Ugurel S;Becker JC
通讯作者: Becker JC
DOI: 10.15252/emmm.201911814
发表时间: 2022-02-07
影响因子: 11.1
作者:
Berestjuk I;Lecacheur M;Carminati A;Diazzi S;Rovera C;Prod'homme V;Ohanna M;Popovic A;Mallavialle A;Larbret F;Pisano S;Audebert S;Passeron T;Gaggioli C;Girard CA;Deckert M;Tartare-Deckert S
通讯作者: Tartare-Deckert S
DOI: 10.3389/fmed.2019.00086
发表时间: 2019-04-26
影响因子: 3.9
作者:
Fujimura, Taku;Sato, Yota;Aiba, Setsuya
通讯作者: Aiba, Setsuya
DOI: 10.2340/00015555-1453
发表时间: 2012-01-01
影响因子: 3.6
作者:
Fujimura, Taku;Kambayashi, Yumi;Aiba, Setsuya
通讯作者: Aiba, Setsuya
DOI: 10.1111/dth.13672
发表时间: 2020-06-16
影响因子: 3.6
作者:
Fujimura, Taku;Kambayashi, Yumi;Aiba, Setsuya
通讯作者: Aiba, Setsuya